https://www.selleckchem.com/products/onx-0914-pr-957.html Sodium/glucose cotransporter 2 (SGLT2) inhibitors decrease plasma triglyceride levels and slightly increase low-density lipoprotein (LDL-c) and high-density lipoprotein cholesterol (HDL-c). However, the mechanisms underlying such changes in the blood lipid profile remain to be determined. We investigated how empagliflozin affects plasma markers of cholesterol absorption and synthesis, and evaluated the relationship between changes in these markers and blood lipids in patients with type 2 diabetes. In a randomized, active-controlled, open-label trial, 51 patients were randomly allocated in 21 ratio to receive empagliflozin 10 mg/day (n = 32) or standard therapy (n = 19) for 12 weeks. We measured plasma levels of lathosterol as a marker of cholesterol synthesis, and campesterol and sitosterol as markers of cholesterol absorption, at baseline and 12 weeks after treatment. In the empagliflozin group, serum HDL-c, but not LDL-c, significantly increased between baseline and 12 weeks (54.4 ± 16.3 vs. 58.8 ± 19.6 This increase may be associated with SGLT2 inhibitor-induced increases in HDL cholesterol. Small case series and case reports indicated atypical persistent pruritic eruptions (PPEs), another type of skin lesions in adult-onset Still's disease (AOSD), imply a worse prognosis than typical evanescent rashes. To investigate clinical characteristics and occurrence in AOSD with PPEs. A retrospective cohort study analyzed 150 AOSD patients with rashes at the First Affiliated Hospital of Zhejiang University from January 2013 to December 2019. AOSD with PPEs had higher lactate dehydrogenase (492.00 U/L vs 382.00 U/L, p＜0.0001) and ferritin (6944.10 ng/mL vs 4286.60 ng/mL, p=0.033), and lower fibrinogen (5.05 g/L vs 5.77 g/L, p=0.014) than those with evanescent rashes. AOSD with PPEs had a higher incidence (17.4% vs 3.1%, p=0.006) and cumulative event rate for MAS (p=0.008), who tended to receive high-dose glucocortic